drugset / Trial / NCT01943292
Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies. The purpose of this study is to assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063).
Timeline
- Start
- 2013-09-02
- Primary completion
- 2014-06-09
- Completion
- 2014-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Defactinib | Small molecule | — | Oral |
Indications
No indication recorded.